In February 2023, the US Food and Drug Administration (FDA) approved a new drug for the treatment of age-related macular degeneration (ARMD). The drug, pegcetacoplan (commercial name Syfovre™), is produced by Appelis Pharmaceuticals. This is the first drug approved for treatment of dry macular degeneration. Among eyecare specialists, enthusiasm around this event has been mixed. There is uncertainty about which patients should […]
The post Pegcetacoplan, a new treatment for macular degeneration first appeared on Science-Based Medicine.from Science-Based Medicine https://sciencebasedmedicine.org/pegcetacoplan-a-new-treatment-for-macular-degeneration/?utm_source=rss&utm_medium=rss&utm_campaign=pegcetacoplan-a-new-treatment-for-macular-degeneration
No comments:
Post a Comment